Human Papilloma Virus
134
20
31
66
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Published Results
23 trials with published results (17%)
Research Maturity
66 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.0%
4 terminated out of 134 trials
94.3%
+7.7% vs benchmark
10%
13 trials in Phase 3/4
35%
23 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (134)
Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.
Hashtag HPV: HPV Vaccine Twitter Education Program
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Merck IIT: RRP Pembro and Lenvatinib
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old
HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV
Developing and Implementing HPV SCREENED
HPV Equity Study: Exploring Cervical Cancer Control in Scotland for Women With Experience of Priority Risks
Impact of Financial Incentives
Blood Biomarkers Based Screening for HPV-driven OPC
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
A Proximity-incentive Strategy for Cervical Cancer Screening
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Impact of Standing Orders Optimization
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Multidimensional and Multimodal Profiling of Oropharyngeal Carcinoma